← Leaderboards
Margie Clapper
Research Inst Of Fox Chase Can Ctr
$5,722,415
Attributed
$5,722,415
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.6M · FY2014–24$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,722,415 · 3
By mechanism
N01$5,722,415 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsColorectal CancerBindingChemopreventive AgentOralTumorigenesisTumorToxic EffectInflammationTissuesFamilyPreventOncogenicIncidenceNeoplastic CellPreclinical EfficacyApoptosisChemopreventionAdenomaMouse ModelCell ProliferationBiological MarkersModificationPremalignant
Grant awards (9)
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA$921,373
N01 · FY2024 · CA · contact PI
TASK ORDER TITLE: NEXT GENERATION GP130/IL-6/STAT3 INHIBITORS FOR THE PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER$1,235,400
N01 · FY2022 · CA · contact PI
TASK ORDER TITLE: MICROBIAL METABOLITE MIMICRY, A NANO-DRUG FOR COLON CANCER PREVENTIONPREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFF$702,469
N01 · FY2022 · CA · contact PI
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINS$614,163
N01 · FY2022 · CA · contact PI
TASK ORDER: PREVENTING LUNG CANCER BY TARGETING ACTIVATED STAT3$779,932
N01 · FY2020 · CA · contact PI
"Novel Non-COX Inhibitory Sulindac Derivative for Colorectal Cancer Chemoprevention with Selective PDE-10 and Wnt/B-Catenin Inhibitory Activity$343,400
N01 · FY2019 · CA · contact PI
Task Order Award "Novel Non-COX Inhibitory Sulindac Derivative for Colorectal Cancer Chemoprevention with Selective PDE-10 and Wnt/B-Catenin Inhibitory Activity$546,703
N01 · FY2018 · CA · contact PI
IGF::OT::IGF THE RESEARCH INSTITUTE FO FOX CHASE CANCER CENTER DUNS: 064367329 CONTRACT ORIENTATION AND KICK-OFF MEETING - HHSN2612012000321 POP 09/22/2015-12/31/2015$3,815
N01 · FY2015 · CA · contact PI
HHSN2612012000151/HHSN2610006Base Contract Title: Preclinical Efficacy and Intermediate Biomarkers. Task Order Title: Modulation of miRNA Expression in Blood or Other Biological Fluids Compared wi$575,160
N01 · FY2014 · CA · contact PI